This report was first published by Endpoints News. To see the original version, click here
Pfizer has discontinued its once-daily obesity pill danuglipron after a patient in one of its clinical trials had a liver injury that may have been drug-induced.
A Pfizer spokesperson told Endpoints News that the case occurred during rapid dose titration of one of the formulations being studied. The study participant was asymptomatic, and their liver enzymes recovered rapidly after treatment discontinuation.
您已閱讀11%（500字），剩余89%（4064字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務。